The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHONY.L Regulatory News (HONY)

  • There is currently no data for HONY

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

NAV and Monthly Update - February 2021

1 Apr 2021 07:00

RNS Number : 2016U
Honeycomb Investment Trust PLC
01 April 2021
 

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, ANY MEMBER STATE OF THE EUROPEAN ECONOMIC AREA (OTHER THAN THE UNITED KINGDOM), CANADA, AUSTRALIA, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL

1 April 2021

Honeycomb Investment Trust plc

Honeycomb Investment Trust plc (the "Company" or "Honeycomb") announces that the Investment Manager's monthly factsheet for 28 February 2021 is now available on its website at http://www.honeycombplc.com.

Net Asset Value per Share

The Company announces that its unaudited Net Asset Value ("NAV") per share as at 28 February 2021 on a cum-income basis was 1,026.4 pence, based on a NAV of £361.9 million, and on an ex-income basis was 1,017.8 pence, based on a NAV of £358.9 million. The NAVs have been calculated by Apex Fund Services (UK) Ltd.

This represents a NAV return of 0.64% for the month of February, which is equivalent to 8.3% per annum.

 

Portfolio Performance

Net Investment Assets increased in the month by £22m, to £593m, driven by drawdowns on existing senior facilities to borrowers across the SME and property sectors.

The Company's ability to continue to deliver uninterrupted strong performance during Covid-19 has demonstrated the portfolio's strong income generation together with downside protection through structural seniority and asset backing with an increasing proportion with real estate backing where the Investment Manager sees significant opportunity.

Pipeline & Market Commentary

The current pipeline of new potential investments is particularly strong, and the Investment Manager has identified even more attractive lending opportunities as the Covid-19 pandemic accelerates the structural challenges facing traditional banks.

As the mainstream banks increasingly focus on only vanilla product sets, the non-bank lending sector is increasingly critical to support local communities through financing SMEs, developing affordable housing, improving the energy efficiency of property, and going forward transportation, creating employment and driving financial inclusion. As the population becomes more engaged in living their lives on a sustainable basis, these lending products enable real people to have real positive impact in their daily lives.

The Company has a near term pipeline of c.£2.7billion to deploy capital in excess of its return targets and, the Investment Manager see significant scope to grow the net assets of Honeycomb over time. To that end, the Board continues to focus on its discount management and to improve the liquidity of the shares.

With the government backed Coronavirus Business Interruption Loan Scheme ("CBILS") being replaced by the Recovery Loan Scheme ("RLS"), the Manager believes opportunities to continue support lending to SMEs through government backed schemes offer compelling risk-adjusted returns for shareholders. To date, the Company has supported CBILS lending and expects opportunities to deploy further capital supporting RLS lending

 

This document is made available for information purposes only and does not contain any representations or constitute an offer to sell or the solicitation of an offer to acquire or subscribe for any securities of the Company. All investments are subject to risk. Prospective investors are advised to seek expert legal, financial, tax and other professional advice before making any investment decision. The value of investments may fluctuate and past performance is no guarantee of future results. 

For further information about this announcement please contact:

Pollen Street Capital - Investment Manager

Matthew Potter / Julian Dale: +44 (0)20 3728 6750

Liberum Capital Limited - Joint Broker

Chris Clarke / Louis Davies: +44 (0)20 3100 2000 

Cenkos Securities plc - Joint Broker

Justin Zawoda-Martin / Rob Naylor: +44 (0)20 7397 8900

Link Company Matters Limited - Corporate Secretary

Paul Johnston: +44 (0)20 7954 9552

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NAVFZGFFVMVGMZM
Date   Source Headline
21st Aug 20177:00 amRNSMonthly Update - July 2017
21st Aug 20177:00 amRNSNet Asset Value - July 2017
18th Aug 20177:00 amRNSHolding(s) in Company - TR-1 Notification
21st Jul 20177:00 amRNSNet Asset Value - June 2017
21st Jul 20177:00 amRNSMonthly Update - June 2017
21st Jun 20177:00 amRNSNet Asset Value(s) - May 2017
21st Jun 20177:00 amRNSMonthly Update - May 2017
5th Jun 201712:48 pmRNSHolding(s) in Company - TR-1 Notification
2nd Jun 20172:15 pmRNSResult of Annual General Meeting
31st May 20174:00 pmRNSResults of Initial Placing
25th May 201712:15 pmRNSPublication of Prospectus and Placing
18th May 20177:00 amRNSNet Asset Value - 30 April 2017
18th May 20177:00 amRNSMonthly Update - April 2017
28th Apr 20175:00 pmRNSNotice of AGM
28th Apr 20175:00 pmRNSAGM and Financial Statement Notification
28th Apr 20177:30 amRNSDividend Declaration - Period to 31 March 2017
28th Apr 20177:00 amRNSAnnual Report and Financial Statements - Dec 2016
25th Apr 201711:23 amRNSMonthly Update - March 2017
25th Apr 20177:00 amRNSNet Asset Value - March 2017
21st Mar 20177:00 amRNSNet Asset Value - February 2017
21st Mar 20177:00 amRNSMonthly Update - February 2017
28th Feb 20179:30 amRNSTransfer of shareholding
28th Feb 20177:00 amRNSDividend Declaration - Period to 31 December 2016
21st Feb 20179:59 amRNSMonthly Update - January 2017
21st Feb 20179:58 amRNSNet Asset Value - January 2017
19th Jan 20172:49 pmRNSMonthly Update - December 2016
19th Jan 20172:12 pmRNSNet Asset Value - December 2016
21st Dec 20164:19 pmRNSMonthly Update - November 2016
20th Dec 20169:41 amRNSHolding(s) in Company - TR-1 Notification
20th Dec 20169:38 amRNSHolding(s) in Company - TR-1 Notification
19th Dec 201610:32 amRNSHolding(s) in Company - TR-1 Notification
16th Dec 20162:57 pmRNSPDMR Shareholding
14th Dec 20167:00 amRNSNet Asset Value - November 2016
12th Dec 20165:16 pmRNSIssue of Equity - Results of placing
9th Dec 201611:46 amRNSProposed Placing
1st Dec 201612:40 pmRNSPublication of a Supplementary Prospectus
18th Nov 20169:54 amRNSMonthly Update - October 2016
14th Nov 20162:55 pmRNSNet Asset Value(s) - October 2016
10th Nov 20165:20 pmRNSDividend Declaration-Period End 30 September 2016
25th Oct 201612:15 pmRNSNet Asset Value - Change to NAV calculation basis
14th Oct 20161:20 pmRNSNet Asset Value(s) - September 2016
30th Sep 20163:18 pmRNSMonthly Update - August 2016
14th Sep 20163:04 pmRNSNet Asset Value(s) - August 2016
30th Aug 20166:06 pmRNSHalf-year Report
26th Aug 20163:29 pmRNSHalf-year Report
26th Aug 20163:19 pmRNSDividend Declaration
25th Aug 20165:42 pmRNSMonthly Update - July 2016
12th Aug 20164:56 pmRNSNet Asset Value(s) - July 2016
15th Jul 20163:15 pmRNSNet Asset Value - June 2016 replacement of 3538E
15th Jul 20162:18 pmRNSPortfolio Update - June 2016

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.